SGB 1534

Known as: SGB-1534 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1985-1993
02419851993

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
The alpha 1-adrenoceptor antagonistic effect of SGB-1534, a novel phenylpiperazine derivative, was examined in the renal vascular… (More)
Is this relevant?
1989
1989
The comparative effects of antihypertensive agents, quinazoline or quinazolinedione residues (prazosin, bunazosin, terazosin, SGB… (More)
Is this relevant?
1989
1989
In conscious normotensive and deoxycorticosterone acetate (DOCA)-salt hypertensive dogs, alpha-adrenoceptor antagonistic and… (More)
Is this relevant?
1988
1988
Effects of prazosin, dobutamine, isoproterenol and SGB-1534, a new alpha-blockade, on congestive heart failure (CHF) in dogs were… (More)
Is this relevant?
1988
1988
Experiments in vitro and in vivo were undertaken to examine possible involvement of a central effect in the hypotensive mechanism… (More)
Is this relevant?
1988
1988
The present study was undertaken to elucidate the effects of a new synthesized phenylpiperazine derivative SGB-1534 on mean… (More)
Is this relevant?
1986
1986
The present study was designed to examine the antiplatelet activity of SGB-1534, 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2… (More)
Is this relevant?
1986
1986
SGB-1534 inhibited the contractile response to norepinephrine (NE), methoxamine (MO) and electrical transmural stimulation in the… (More)
Is this relevant?
1985
1985
The antihypertensive activities of SGB-1534, 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2,4 (1H,3H)-quinazolinedione… (More)
Is this relevant?
1985
1985
The cardiovascular effects of SGB-1534 (3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]-2,4(1H,3H)-quinazolinedione monohydrochloride… (More)
Is this relevant?